Shift From Adalimumab Originator to Biosimilars in Denmark
Brand-name adalimumab (Humira, hereinafter originator) is by far the most cost-intensive pharmaceutical product in the US with global sales of $19.9 billion in 2018. Five adalimumab biosimilars have been approved by the US Food and Drug Administration, but none are marketed owing to patent disputes. The first to become marketed is expected in January 2023.
